TCD With Transfusions Changing to Hydroxyurea
TCD 输血改为羟基脲
基本信息
- 批准号:8520382
- 负责人:
- 金额:$ 320.73万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-08-21 至 2015-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAdverse effectsAdverse eventAllergic ReactionAlternative TherapiesAnemiaAntibodiesAntibody FormationArrhythmiaAutoantibodiesBlood TransfusionBrainCerebrovascular DisordersCerebrumCessation of lifeChelation TherapyChildChronicClinicalCoupledDataDeferoxamineDeferoxamine MethanesulfonateDiabetes MellitusErythrocyte TransfusionErythrocytesEventExcisionFailureFrequenciesGoalsGrowth and Development functionHeightHepaticHospitalizationHypotensionIncidenceInfectionInfectious AgentInternal carotid artery structureIronIron OverloadIsoantibodiesLaboratoriesLeadLiverLiver CirrhosisLiver FibrosisMagnetic Resonance ImagingMaintenanceMeasurementMorbidity - disease rateMyelosuppressionNeurocognitive DeficitNeurologicOrganPainPatientsPhasePriapismPrimary PreventionProphylactic treatmentQuality of lifeRandomized Clinical TrialsReactionRiskSafetySickle CellSickle Cell AnemiaSourceStagingStrokeStroke preventionSudden DeathSyncopeTimeToxic effectTransfusionVenous blood samplingWeightabstractingacute chest syndromechelationclinical efficacyfunctional statushigh riskhydroxyureairon chelation therapymiddle cerebral arterymortalitymotor deficitneuropsychologicalnon-complianceototoxicitypreventscreeningtreatment durationvaso-occlusive pain
项目摘要
DESCRIPTION (provided by applicant):
Stroke occurs in 5-10% of children with SCA, and is a devastating clinical event that results in severe motor and neurocognitive deficits. To help prevent an initial (primary) stroke, young patients with SCA can receive periodic TCD screening to identify children with elevated arterial velocities in the cerebral vasculature, which portends increased primary stroke risk. For children with time-averaged maximum velocities (TAMV) in the middle cerebral artery (MCA) or internal carotid artery (ICA) elevated to the "abnormal" range (=200cm/sec), chronic erythrocyte transfusions significantly lower the risk of primary stroke. In this setting, transfusions can prevent first stroke but have serious side-effects limiting their long-term utility. Transfusions transmit infectious agents, lead to erythrocyte alloantibody or autoantibody formation, and result in iron overload. Transfusion acquired iron overload is recognized as a source of morbidity and mortality for young patients with SCA receiving transfusions for prevention of primary stroke. Chelation therapy can help prevent iron accumulation, but is difficult to tolerate and non-compliance is common. An alternative to transfusion prophylaxis for primary stroke prevention is clearly needed, especially one that also provides an opportunity to address the issue of transfusion acquired iron overload. We propose a Phase III randomized clinical trial for children with sickle cell anemia (SCA) and abnormal Transcranial Doppler (TCD) velocities, termed the "TCD With Transfusions Changing to Hydroxyurea" (TWiTCH) trial. Our hypothesis is that hydroxyurea can maintain a similar TCD velocity as erythrocyte transfusions, and therefore serve as non-inferior therapy, for primary stroke prevention in high risk children with SCA. The primary aim of the TWiTCH trial is to compare standard therapy (transfusions) to alternative therapy (hydroxyurea) for maintenance of TCD velocities in children with SCA on chronic transfusions for abnormal TCD velocities. Additional aims of TWiTCH include comparison of standard to alternative therapy for incidence of primary stroke, determination of the frequency of non-stroke neurological events and other sickle cell-related events, management of iron overload, assessment of growth and development, recording of adverse events, and measurement of quality of life. (End of Abstract)
描述(由申请人提供):
中风发生在5-10%的SCA儿童中,并且是导致严重运动和神经认知缺陷的破坏性临床事件。为了帮助预防初始(原发性)卒中,年轻SCA患者可以接受定期TCD筛查,以识别脑血管系统中动脉流速升高的儿童,这预示着原发性卒中风险增加。对于大脑中动脉(MCA)或颈内动脉(伊卡)的时间平均最大流速(TAMV)升高至“异常”范围(= 200 cm/sec)的儿童,长期红细胞输注可显著降低原发性卒中的风险。在这种情况下,输血可以预防首次中风,但有严重的副作用,限制其长期效用。输血传播感染因子,导致红细胞同种抗体或自身抗体形成,并导致铁过载。输血获得性铁过载被认为是年轻SCA患者接受输血预防原发性卒中的发病率和死亡率的来源。螯合疗法可以帮助防止铁的积累,但难以耐受,不遵守是常见的。显然需要一种替代预防性输血的方法来预防卒中,特别是一种还提供了解决输血获得性铁过载问题的机会的方法。我们提出了一个III期随机临床试验的儿童镰状细胞贫血(SCA)和异常经颅多普勒(TCD)速度,被称为“TCD与输液改为羟基脲”(TWiTCH)试验。我们的假设是,羟基脲可以维持与红细胞输注相似的TCD速度,因此可以作为非劣效治疗,用于SCA高危儿童的一级卒中预防。TWiTCH试验的主要目的是比较标准治疗(输血)与替代治疗(羟基脲)在维持因TCD速度异常而长期输血的SCA儿童的TCD速度方面的效果。TWiTCH的其他目的包括比较标准疗法与替代疗法的原发性中风发生率、确定非中风神经系统事件和其他镰状细胞相关事件的频率、管理铁超载、评估生长和发育、记录不良事件和测量生活质量。(End摘要)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Russell E Ware其他文献
NEUTROPENIA ASSOCIATED WITH ELEVATED TNF-α IN COMBINED IMMUNODEFICIENCY(CID). • 54
- DOI:
10.1203/00006450-199604001-00073 - 发表时间:
1996-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Terry O Harville;Stuart S Winter;Gregory A Hanissian;James E Gern;Russell E Ware - 通讯作者:
Russell E Ware
A Population Pharmacokinetic Analysis of l-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects
镰状细胞病患者 L-谷氨酰胺暴露的群体药代动力学分析:剂量和食物影响的评估
- DOI:
10.1007/s40262-024-01349-4 - 发表时间:
2024 - 期刊:
- 影响因子:4.5
- 作者:
Alina Sadaf;M. Dong;A. Pfeiffer;Teresa S. Latham;T. Kalfa;A. Vinks;Russell E Ware;Charles T Quinn - 通讯作者:
Charles T Quinn
CLINICAL SIGNIFICANCE OF THE ANTINUCLEAR ANTIBODY (ANA) TEST IN CHILDHOOD IMMUNE THROMBOCYTOPENIC PURPURA (ITP). • 972
- DOI:
10.1203/00006450-199604001-00994 - 发表时间:
1996-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Sherri A Zimmerman;Russell E Ware - 通讯作者:
Russell E Ware
Malaria prophylaxis in sickle cell anaemia: some answers, more questions
镰状细胞贫血中的疟疾预防:一些答案,更多问题
- DOI:
10.1016/s1473-3099(24)00745-x - 发表时间:
2025-06-01 - 期刊:
- 影响因子:31.000
- 作者:
Thomas N Williams;Russell E Ware - 通讯作者:
Russell E Ware
CLONAL EXPANSION OF Vβ8+ T LYMPHOCYTES IN CHRONIC IMMUNE THROMBOCYTOPENIC PURPURA. • 892
- DOI:
10.1203/00006450-199604001-00914 - 发表时间:
1996-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Denise M Adams;Thad A Howard;Russell E Ware - 通讯作者:
Russell E Ware
Russell E Ware的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Russell E Ware', 18)}}的其他基金
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia
利用羟基脲 (REACH) 在各大洲实现有效性:羟基脲治疗镰状细胞性贫血儿童的 I/II 期初步研究
- 批准号:
10001581 - 财政年份:2017
- 资助金额:
$ 320.73万 - 项目类别:
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia
利用羟基脲 (REACH) 在各大洲实现有效性:羟基脲治疗镰状细胞性贫血儿童的 I/II 期初步研究
- 批准号:
9764461 - 财政年份:2017
- 资助金额:
$ 320.73万 - 项目类别:
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia
利用羟基脲 (REACH) 在各大洲实现有效性:羟基脲治疗镰状细胞性贫血儿童的 I/II 期初步研究
- 批准号:
10223406 - 财政年份:2017
- 资助金额:
$ 320.73万 - 项目类别:
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia
利用羟基脲 (REACH) 在各大洲实现有效性:羟基脲治疗镰状细胞性贫血儿童的 I/II 期初步研究
- 批准号:
10444370 - 财政年份:2017
- 资助金额:
$ 320.73万 - 项目类别:
Realizing Effectiveness Across Continents with Hydroxyurea(REACH): A Phase I/II Pilot Study of Hyroxyurea for Children with Sickle Cell Anemia
利用羟基脲 (REACH) 在各大洲实现有效性:羟基脲治疗镰状细胞性贫血儿童的 I/II 期初步研究
- 批准号:
10679001 - 财政年份:2017
- 资助金额:
$ 320.73万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 320.73万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 320.73万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 320.73万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 320.73万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 320.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 320.73万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 320.73万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 320.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 320.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 320.73万 - 项目类别:
Grant-in-Aid for Scientific Research (C)